Tyrell J. Simkins

Neurology

3160 Folsom Blvd Ste 2100
Sacramento, CA 95816

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM.

Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM.

Journal: European journal of heart failure

Published: February 18, 2026

A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.

A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.

Journal: Clinical pharmacokinetics

Published: December 17, 2025

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.

Journal: Circulation. Heart failure

Published: December 05, 2025

Clinical Evaluation of Drug-Drug Interactions With Aficamten.

Clinical Evaluation of Drug-Drug Interactions With Aficamten.

Journal: Clinical and translational science

Published: November 24, 2025

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

Journal: Muscle & nerve

Published: October 29, 2025

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Journal: European heart journal

Published: July 30, 2025

Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials.

Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials.

Journal: Heart rhythm

Published: July 30, 2025

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Journal: Journal of cardiac failure

Published: July 23, 2025

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: June 27, 2025

Hospitalizations as an outcome measure in COURAGE-ALS.

Hospitalizations as an outcome measure in COURAGE-ALS.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: June 12, 2025

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Journal: JAMA neurology

Published: March 24, 2025

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants.

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants.

Journal: Clinical and translational science

Published: December 12, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026